Adherence: A Key to Successful Treatment of Cystic Fibrosis
Released On
March 17, 2023
Expires On
March 17, 2024
Media Type
Internet
Completion Time
1 hour 45 minutes
Specialty
Pediatrics, Primary Care, Pulmonology
Topic(s)
Cystic Fibrosis
This activity is provided by National Jewish Health.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Credit Available
- Physicians — maximum of 1.75 AMA PRA Category 1 Credit(s)™
- Registered Nurses - 1.75 contact hours
- Pharmacists: 1.75 contact hours (0.175 CEUs)
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
Pediatric Pulmonologists, Pulmonologists, Primary Care Physicians, along with all other healthcare professionals who may manage the CF patient including advanced practice providers, pharmacists, and nurses.
Program Overview
The approval of CFTR modulators has revolutionized the treatment of people with CF. However, their use alongside conventional therapies such as antibiotics, mucolytics, and bronchodilators remains a point of confusion among many healthcare providers. In this activity, expert faculty will review CF pathophysiology and therapies targeting infections and lung function and improving patient quality of life. Faculty will also address concerns with drug complexity, burden, and adherence issues.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate the role of CF therapies in clinical management of lung infections, pulmonary exacerbations, and preservation of lung function
- Analyze new and emerging clinical trial and real-world data on pulmonary outcomes for CF therapies
- Utilize evidence-based strategies to improve treatment adherence in CF
Faculty
Jennifer L. Taylor-Cousar, MD, MSCS, ATSF (Program Chair)
President, Medical Staff
Medical Director, Clinical Research Services
Co-Director and CF TDC Director, Adult CF Program
Professor, Departments of Medicine and Pediatrics,
Divisions of Pulmonary, Critical Care and Sleep Medicine
and Pediatric Pulmonary Medicine
National Jewish Health
Divisions of Pulmonary Sciences and Critical Care Medicine and Pediatric Pulmonology
University of Colorado Anschutz Medical Campus
Denver, CO
David Nichols, MD
David Nichols, MD
Professor of Pediatrics (affiliate)
University of Washington School of Medicine
Seattle, WA
Kristin Riekert, PhD
Professor, Johns Hopkins Division of Pulmonary & Critical Care
Director, Johns Hopkins Adherence Research Center
Co-Chair, Success with Therapies Research Consortium
Baltimore MD
Edith Zemanick, MD, MSCS
Professor of Pediatrics
Medical Director Clinical Research, Breathing Institute
Director, Cystic Fibrosis Foundation Therapeutics Development Center
Children’s Hospital Colorado
University of Colorado School of Medicine
Denver, CO
Accreditation and Designation Statements
Physicians
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
National Jewish Health designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Pharmacists
National Jewish Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
National Jewish Health designates this enduring material for 1.75 contact hours (0.175 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: UAN 0831-0000-23-002-H01-P Activity Type: Application-based
Registered Nurses
Nurses Provider approved by the California Board of Registered Nursing, Provider Number 12724 for 1.75 contact hours
Disclosure of Financial Relationships for Individuals in Control of Content
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.
All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.
Disclosures of Conflicts of Interest
Faculty
Jennifer Taylor-Cousar, MD, MSCS, ATSF
Reports the following relevant financial relationships:
- Consultant: 4DMT, AbbVie, Vertex Pharmaceuticals
- Speaker: Vertex Pharmaceuticals
- Investigator: Eloxx Pharmaceuticals
David Nichols, MD
Reports the following relevant financial relationships:
- Consultant (former): Nabriva, Respirion, and BiomX
- Advisory board (former): Vertex Pharmaceuticals
Kristin Riekert, PhD
Reports the following relevant financial relationships:
- Speaker: Vertex Pharmaceuticals
Edith Zemanick, MD, MSCS
Reports the following relevant financial relationships:
- Advisory board (former): Vertex Pharmaceuticals
- Investigator: Vertex Pharmaceuticals
Planners and Reviewers
Elyce Bowron, MEd, has no relevant financial relationships.
Meghan Brenner, MA, has no relevant financial relationships.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant financial relationships.
Ann Mullen, RN, CNS, CDE, has no relevant financial relationships.
Jerry Nick MD, has no relevant financial relationships.
Unlabeled and Investigational Usage
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.
Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.
Disclaimer Statement
National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
Privacy Policy
The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).
We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.
If you decide to register for an Internet CME program, we will collect personal
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures
- Participate in the online activity
- Submit an evaluation form and complete the post-test with a passing score of at least 2 out of 3
A certificate of participation will be emailed to the participant.
Course Viewing Requirements
Hardware/Software Requirements
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Contact Information
For CME questions please contact: [email protected].
Resources
Cystic Fibrosis Foundation: Resources for Adherence
https://www.cff.org/medical-professionals/more-taking-medications
https://www.cff.org/medical-professionals/partnerships-sustaining-daily-care